Publications
Detailed Information
5,7-dihydroxy-3,4,6-trimethoxyflavone inhibits the inflammatory effects induced by Bacteroides fragilis enterotoxin via dissociating the complex of heat shock protein 90 and IκBα and IκB kinase-γ in intestinal epithelial cell culture
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J. M. | - |
dc.contributor.author | Lee, D. H. | - |
dc.contributor.author | Kim, J. S. | - |
dc.contributor.author | Lee, J. Y. | - |
dc.contributor.author | Kim, Y. -J. | - |
dc.contributor.author | Jung, H. C. | - |
dc.contributor.author | Kim, S. I. | - |
dc.contributor.author | Oh, Y. -K. | - |
dc.contributor.author | Park, H. -G. | - |
dc.date.accessioned | 2012-05-23T08:52:41Z | - |
dc.date.available | 2012-05-23T08:52:41Z | - |
dc.date.issued | 2009-03 | - |
dc.identifier.citation | CLINICAL AND EXPERIMENTAL IMMUNOLOGY; Vol.155 3; 541-551 | ko_KR |
dc.identifier.issn | 0009-9104 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76354 | - |
dc.description.abstract | Enterotoxin produced by enterotoxigenic Bacteroides fragilis (BFT) has been associated with mucosal inflammation and diarrhoeal diseases. In this study, the anti-inflammatory molecular mechanism of 5,7-dihydroxy-3,4,6-trimethoxyflavone (eupatilin) was characterized in an HT-29 intestinal epithelial cell line stimulated with BFT. Pre-treatment of HT-29 cells with eupatilin decreased the production significantly of both interleukin (IL)-8 and prostaglandin E(2) induced by BFT in a dose-dependent manner. BFT-activated nuclear factor-kappaB (NF-kappa B) signals in HT-29 cells and pretreatment with eupatilin suppressed NF-kappa B activation that resulted in the significant inhibition of IL-8 and cyclo-oxygenase-2 expression. BFT-induced phosphorylation of both I kappa B alpha and I kappa B kinase (IKK) signals was prevented in eupatilin-pretreated HT-29 cells. Transfection of siRNA for IKK-alpha and IKK-beta decreased the production of IL-8 and prostaglandin E(2); however, the transfection of IKK-beta siRNA showed a more significant reduction of BFT-induced I kappa B alpha phosphorylation compared with that of IKK-alpha siRNA. In addition, herbimycin A, a specific inhibitor of heat shock protein 90 (Hsp90), decreased the BFT-induced activation of IKK and NF-kappa B, suggesting that Hsp90 is associated with a pathway of IKK-NF-kappa B-IL-8/cyclo-oxygenase-2 gene signalling. Furthermore, eupatilin dissociated the complex between Hsp90 and IKK-gamma in BFT-stimulated HT-29 cells. These results suggest that eupatilin can suppress the NF-kappa B signalling pathway by targeting the Hsp90-IKK-gamma complex in intestinal epithelial cells and may attenuate BFT-induced inflammatory responses. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL | ko_KR |
dc.subject | Bacteroides fragilis enterotoxin | ko_KR |
dc.subject | NF-κB | ko_KR |
dc.subject | eupatilin | ko_KR |
dc.subject | IκB kinase, | ko_KR |
dc.subject | Hsp90 | ko_KR |
dc.title | 5,7-dihydroxy-3,4,6-trimethoxyflavone inhibits the inflammatory effects induced by Bacteroides fragilis enterotoxin via dissociating the complex of heat shock protein 90 and IκBα and IκB kinase-γ in intestinal epithelial cell culture | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1111/j.1365-2249.2008.03849.x | - |
dc.citation.journaltitle | CLINICAL AND EXPERIMENTAL IMMUNOLOGY | - |
dc.description.citedreference | Kim JM, 2008, EUR J IMMUNOL, V38, P2190, DOI 10.1002/eji.200838191 | - |
dc.description.citedreference | Kim JM, 2008, LAB INVEST, V88, P541, DOI 10.1038/labinvest.2008.16 | - |
dc.description.citedreference | Lee JY, 2007, J MOL MED-JMM, V85, P1393, DOI 10.1007/s00109-007-0237-7 | - |
dc.description.citedreference | Biesalski HK, 2007, CURR OPIN CLIN NUTR, V10, P724 | - |
dc.description.citedreference | Marcos LA, 2007, J INFECTION, V55, P385, DOI 10.1016/j.jinf.2007.07.016 | - |
dc.description.citedreference | Kim JM, 2007, INFECT IMMUN, V75, P3373, DOI 10.1128/IAI.01940-06 | - |
dc.description.citedreference | Gonzalez-Gallego J, 2007, NUTR HOSP, V22, P287 | - |
dc.description.citedreference | Park KA, 2007, CARCINOGENESIS, V28, P71, DOI 10.1093/carcin/bg1094 | - |
dc.description.citedreference | RABIZADEH S, 2007, INFLAMM BOWEL DIS, V13, P1475 | - |
dc.description.citedreference | Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004 | - |
dc.description.citedreference | Kim JM, 2006, EUR J IMMUNOL, V36, P2446, DOI 10.1002/eji.200535808 | - |
dc.description.citedreference | Park SC, 2006, J GASTROENTEROL, V41, P772, DOI 10.1007/s00535-006-1854-6 | - |
dc.description.citedreference | Surh YJ, 2005, J NUTR, V135, p2993S | - |
dc.description.citedreference | Kim JM, 2005, EUR J IMMUNOL, V35, P2648, DOI 10.1002/eji.200526321 | - |
dc.description.citedreference | Puupponen-Pimia R, 2005, BIOFACTORS, V23, P243 | - |
dc.description.citedreference | Wu SG, 2004, INFECT IMMUN, V72, P5832, DOI 10.1128/IAI.72.10.5832-5839.2004 | - |
dc.description.citedreference | Kim DH, 2004, BIOCHEM PHARMACOL, V68, P1081, DOI 10.1016/j.bcp.2004.04.027 | - |
dc.description.citedreference | Basset C, 2004, DIGEST DIS SCI, V49, P1425 | - |
dc.description.citedreference | Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705 | - |
dc.description.citedreference | Kim JM, 2002, CLIN EXP IMMUNOL, V130, P59 | - |
dc.description.citedreference | Chen GQ, 2002, MOL CELL, V9, P401 | - |
dc.description.citedreference | Sears CL, 2001, TOXICON, V39, P1737 | - |
dc.description.citedreference | Seo HJ, 2001, MUTAT RES-GEN TOX EN, V496, P191 | - |
dc.description.citedreference | Kim JM, 2001, CLIN EXP IMMUNOL, V123, P421 | - |
dc.description.citedreference | Kim JM, 2000, DIGEST DIS SCI, V45, P2436 | - |
dc.description.citedreference | Inoue H, 2000, J BIOL CHEM, V275, P28028 | - |
dc.description.citedreference | Lewis J, 2000, J BIOL CHEM, V275, P10519 | - |
dc.description.citedreference | Sanfilippo L, 2000, CLIN EXP IMMUNOL, V119, P456 | - |
dc.description.citedreference | Karin M, 2000, ANNU REV IMMUNOL, V18, P621 | - |
dc.description.citedreference | Zhang GM, 1999, CLIN INFECT DIS, V29, P590 | - |
dc.description.citedreference | Elewaut D, 1999, J IMMUNOL, V163, P1457 | - |
dc.description.citedreference | Rothwarf DM, 1998, NATURE, V395, P297 | - |
dc.description.citedreference | Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675 | - |
dc.description.citedreference | Yamaoka S, 1998, CELL, V93, P1231 | - |
dc.description.citedreference | Chen ZJ, 1996, CELL, V84, P853 | - |
dc.description.citedreference | SEARS CL, 1995, CLIN INFECT DIS, V20, pS142 | - |
dc.description.tc | 6 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.